Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + Fulvestrant in Recurrent Low-grade Serous Ovarian Cancer
NCT05113368Phase 2Recruiting
- Start
- Jun 2022
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in Low grade serous ovarian cancer (LGSOC). Started Jun 2022; status: recruiting.
02
Drugs
regorafenib
03
Conditions
Low grade serous ovarian cancer (LGSOC)
Beyond the preview
Go deeper on NCT05113368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113368.